Skip to main content

Table 3 1-year clinical outcomes in propensity score matched patients

From: Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus

Outcomes

SGLT2i group

DPP-4i group

Unadjusted analysis

IPTW-adjusted analysis

(n = 186)

(n = 593)

HR (95% CI)

p-value

HR (95% CI)

p-value

MACE

19 (10.2)

58 (9.8)

0.96 (0.57–1.61)

0.873

0.99 (0.46–2.14)

0.983

All-cause mortality

0 (0.0)

11 (1.8)

NA

NA

NA

NA

Cardiac death

0 (0.0)

5 (0.8)

NA

NA

NA

NA

Non-cardiac death

0 (0.0)

6 (1.0)

NA

NA

NA

NA

Myocardial infarction

2 (1.1)

9 (1.5)

1.47 (0.32–6.82)

0.621

2.78 (0.31–24.90)

0.362

Any revascularization

12 (6.4)

22 (3.7)

0.56 (0.28–1.13)

0.108

0.68 (0.26–1.74)

0.418

CVA

4 (2.1)

8 (1.3)

0.67 (0.20–2.23)

0.513

1.43 (0.24–8.71)

0.697

Rehospitalization

3 (1.6)

19 (3.2)

2.05 (0.61–6.94)

0.247

1.58 (0.28–8.99)

0.603

  1. Categorical values are presented as percentage (number)
  2. CI = confidence interval; CVA = cerebrovascular accident; DPP-4i = dipeptidyl peptidase-4 inhibitors; HR = hazard ratio; NA = not applicable; IPTW = inverse probability of treatment weighting; MACE = major adverse composite event; SGLT2i = sodium-glucose cotransporter 2 inhibitors